Etrumadenant

DRUG18 trials

Sponsors

Arcus Biosciences Inc., Arcus Biosciences, Inc., David Oh, Washington University School of Medicine, Jennifer Choe

Conditions

Androgen-Resistant Prostatic NeoplasmsBladder CancerBreast CancerCastration Resistant Prostatic NeoplasmsCastration-resistant Prostate CancerColorectal CancerDedifferentiated LiposarcomaEndometrial Cancer

Phase 1

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

CompletedNCT03629756

Arcus Biosciences, Inc.Bladder Cancer, Breast Cancer, Castration-resistant Prostate Cancer +9

Start: 2018-07-24End: 2021-09-03Updated: 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

CompletedNCT03719326

Arcus Biosciences, Inc.Ovarian Cancer, TNBC - Triple-Negative Breast Cancer

Start: 2018-10-15End: 2021-07-02Updated: 2024-05-24

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

CompletedNCT03720678

Arcus Biosciences, Inc.Colorectal Cancer, GastroEsophageal Cancer

Start: 2018-11-18End: 2021-06-25Updated: 2024-05-24

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

CompletedNCT03846310

Arcus Biosciences, Inc.Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung +1

Start: 2019-04-01End: 2024-11-18Updated: 2024-12-09

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

CompletedNCT04381832

Arcus Biosciences, Inc.Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant +1

Start: 2020-07-07End: 2024-08-30Updated: 2025-07-22

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

CompletedNCT04660812

Arcus Biosciences, Inc.Metastatic Colorectal Cancer

Start: 2021-05-10End: 2025-09-05Updated: 2025-10-20

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

WithdrawnNCT04892875

Jennifer ChoeHead and Neck Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma +7

Start: 2023-12-31End: 2026-12-31Updated: 2023-11-30

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

CompletedNCT05154136

Arcus Biosciences, Inc.Healthy Participants

Start: 2021-10-20End: 2021-12-10Updated: 2024-05-24

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

CompletedNCT05277012

Arcus Biosciences, Inc.Healthy Participants

Start: 2022-02-10End: 2022-03-31Updated: 2024-05-24

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

CompletedCTIS2024-511158-36-00

Arcus Biosciences Inc.Metastatic colorectal cancer

Start: 2021-08-05End: 2025-06-10Target: 57Updated: 2025-07-08

Phase 2

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

RecruitingNCT03821246

David OhLocalized Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer

Start: 2019-10-30End: 2026-04-30Target: 68Updated: 2025-05-15

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

CompletedNCT04262856

Arcus Biosciences, Inc.Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer +1

Start: 2020-05-28End: 2025-07-09Updated: 2025-08-26

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Active, not recruitingNCT04791839

Washington University School of MedicineNon-small Cell Carcinoma, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer

Start: 2021-08-04End: 2030-06-30Updated: 2025-11-05

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

TerminatedNCT05177770

Coherus Oncology, Inc.Metastatic Castration-resistant Prostate Cancer, Prostate Cancer

Start: 2022-01-17End: 2023-04-05Updated: 2025-05-08

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Active, not recruitingNCT05335941

M.D. Anderson Cancer CenterMetastatic Cancer, Urothelial Carcinoma

Start: 2023-06-13End: 2027-09-30Updated: 2026-03-04

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Active, not recruitingNCT05886634

Memorial Sloan Kettering Cancer CenterDedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma +4

Start: 2023-05-23End: 2027-05-23Updated: 2025-10-20

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

RecruitingNCT05915442

Catherine SpinaOligometastatic Prostate Cancer

Start: 2023-07-01End: 2028-12-31Target: 23Updated: 2025-05-20

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

RecruitingNCT06048484

Gulam ManjiPancreatic Ductal Adenocarcinoma

Start: 2024-05-10End: 2027-04-01Target: 60Updated: 2026-02-27

Related Papers

The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

2026-03-23

ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2024-06-017 citations

A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).

Journal of Clinical Oncology2024-01-29

AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.

Journal of Clinical Oncology2024-01-20

660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)

Regular and Young Investigator Award Abstracts2023-10-311 citations

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer2023-06-0183 citations

Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).

Journal of Clinical Oncology2023-06-015 citations

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-10-2055 citations

Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients

Cancer Research2021-07-016 citations

ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-05-2013 citations

Abstract PS12-12: Efficacy and safety of AB928 plus pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with metastatic ovarian and triple negative breast cancer

Cancer Research2021-02-154 citations

338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6)

Regular and Young Investigator Award Abstracts2020-11-01

Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)

Cancer Research2020-08-151 citations

ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2020-05-2012 citations

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

Journal of Clinical Oncology2019-05-2032 citations